Ascletis Reports Positive Preclinical Data For Once-Weekly Oral Obesity Drug Pipeline

Ascletis Pharma reported positive preclinical data for its once-weekly oral peptide pipeline targeting obesity and other metabolic diseases. The company highlighted extended half-lives and oral bioavailability; no numerical results or clinical-stage data were provided.